Aaron Diamond AIDS Research Center, New York, New York, USA.
J Virol. 2012 Sep;86(17):9432-42. doi: 10.1128/JVI.00852-12. Epub 2012 Jun 27.
We previously reported efficient transmission of the pathogenic R5 simian-human immunodeficiency virus SHIV(SF162P3N) isolate in Indian rhesus macaques by intravenous and intrarectal inoculations, with a switch to CXCR4 coreceptor usage in ∼50% of infected animals that progressed rapidly to disease. Since women continue to be disproportionately affected by HIV, we developed an animal model based on the intravaginal challenge of female rhesus monkeys with SHIV(SF162P3N) and sought to validate the utility of this model to study relevant aspects of HIV transmission and pathogenesis. The effect of viral dose on infection outcome was evaluated to determine the optimal conditions for the evaluation of HIV-1 preventive and therapeutic strategies. We found that the virus can successfully cross the vaginal mucosal surface to establish infection and induce disease with coreceptor switch, but with lower efficiencies compared to intravenous and rectal transmissions. In contrast to intrarectal infection, peak and cumulative viral load over a 1 year-infection period were significantly greater in macaques exposed intravaginally to lower rather than higher inoculum doses. Moreover, low and transient viremia was observed only in macaques that were challenged intravaginally twice within the same day with a high dose of virus, which can be seen as doubling the dose. Taken together, these results show that SHIV(SF162P3N) can successfully transmit across the genital mucosa, undergo coreceptor switch, and induce disease. However, the administered dose appears to impact SHIV(SF162P3N) vaginal infection outcome in an unexpected manner.
我们之前报道了致病性 R5 猴免疫缺陷病毒 SHIV(SF162P3N)通过静脉内和直肠内接种在印度恒河猴中有效传播的情况,约 50%的受感染动物发生了 CXCR4 核心受体的转换,迅速进展为疾病。由于女性继续不成比例地受到 HIV 的影响,我们开发了一种基于雌性恒河猴阴道内接种 SHIV(SF162P3N)的动物模型,并试图验证该模型在研究 HIV 传播和发病机制的相关方面的效用。评估病毒剂量对感染结果的影响,以确定评估 HIV-1 预防和治疗策略的最佳条件。我们发现,该病毒可以成功地穿过阴道黏膜表面建立感染并诱导疾病发生,同时发生核心受体转换,但与静脉内和直肠内传播相比,效率较低。与直肠内感染不同,在阴道内暴露于较低而非较高接种剂量的病毒后,在 1 年感染期内,病毒载量峰值和累积量显著更高。此外,只有在同一天内阴道内两次受到高剂量病毒挑战的猕猴中观察到低且短暂的病毒血症,这可以视为剂量加倍。综上所述,这些结果表明,SHIV(SF162P3N)可以成功地穿过生殖黏膜传播,发生核心受体转换,并诱导疾病。然而,给予的剂量似乎以出人意料的方式影响 SHIV(SF162P3N)阴道感染的结果。